Authors:
Ben Wilson, MD1, Joanne Xiu, PhD2, Tiffany Redfern, MD1, Michael Ulm, MD1, Ramesh Narayanan, PhD3, Adam ElNaggar, MD1
Objectives:
Androgen receptors (AR) are expressed in up to 55% of ERα-negative breast cancers overall and up to 35% of those classified as TNBC. Similarly, AR is expressed in approximately 40% of high grade serous ovarian cancer (HGSOC). The development of AR splice variants (AR-SV), particularly AR-V7, has been shown to be a poor prognostic feature, and mechanism of androgen resistance in breast and prostate cancers. We sought to determine if AR-V7 was present in HGSOC and if there was a correlation with platinum sensitivity and/or treatment outcomes.
External Link
